INHIBITOR OF CELLULAR NIACINAMIDE MONONUCLEOTIDE FORMATION AND USE OF THE SAME IN CANCER THERAPY

PROBLEM TO BE SOLVED: To provide biologically active compounds which inhibit cellular niacinamide mononucleotide formation.SOLUTION: Biologically active compounds are screened by: culturing specific cultured cells such as HepG2 cells, U-87MG cells and MCF-7 M1 cells under the presence of compounds w...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	WOSIKOWSKI KATJA, SEIBEL KLAUS, LOESER ROLAND, REITER FRIEDEMANN, SCHULZ MICHAEL, SAINDA ISABEL, BIEDERMANN ELFI, SCHEIN BARBARA, HASMANN MAX, EISENBURGER ROLF, RATTEL BENNO, VOGT KLAUS
Format:	Patent
Sprache:	eng
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES ENZYMOLOGY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROCESSES OF PREPARING SUCH COMPOSITIONS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS TESTING VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	PROBLEM TO BE SOLVED: To provide biologically active compounds which inhibit cellular niacinamide mononucleotide formation.SOLUTION: Biologically active compounds are screened by: culturing specific cultured cells such as HepG2 cells, U-87MG cells and MCF-7 M1 cells under the presence of compounds whose inhibitory activity in formation of [14C] niacinamide and cellular niacinamide mononucleotide is tested; and measuring the quantities of formation of labelled niacinamide mononucleotide, NAD and NADP. As a result of the screening, such compounds as N-(4-{1-[4-(1-benzhydril-piperigine-4-yl)-butyl]-piperigine-4-yl}-butyl)-3-pyrigine-3-ylpropane acid amide, and N-{2-[5-(4-benzhydril-piperazine-1-yl-metyl)-1-methyl-1H-pyrrole-2-yl]-ethyl}-3-pyrigine-3-yl acryl amide are provided.